Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo - Université Paris Cité Accéder directement au contenu
Article Dans Une Revue Molecular Cancer Therapeutics Année : 2021

Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo

Résumé

B-cell maturation antigen (BCMA) is an attractive therapeutic target highly expressed on differentiated plasma cells in multiple myeloma and other B-cell malignancies. GSK2857916 (belantamab mafodotin, BLENREP) is a BCMA-targeting antibody-drug conjugate approved for the treatment of relapsed/refractory multiple myeloma. We report that GSK2857916 induces immunogenic cell death in BCMA-expressing cancer cells and promotes dendritic cell activation in vitro and in vivo. GSK2857916 treatment enhances intratumor immune cell infiltration and activation, delays tumor growth, and promotes durable complete regressions in immune-competent mice bearing EL4 lymphoma tumors expressing human BCMA (EL4-hBCMA). Responding mice are immune to rechallenge with EL4 parental and EL4-hBCMA cells, suggesting engagement of an adaptive immune response, immunologic memory, and tumor antigen spreading, which are abrogated upon depletion of endogenous CD8 þ T cells. Combinations with OX40/OX86, an immune agonist antibody, significantly enhance antitumor activity and increase durable complete responses, providing a strong rationale for clinical evaluation of GSK2857916 combinations with immunotherapies targeting adaptive immune responses, including T-cell-directed checkpoint modulators.

Domaines

Cancer
Fichier principal
Vignette du fichier
1941.full.pdf (1.12 Mo) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03568613 , version 1 (12-02-2022)

Identifiants

Citer

Rocio Montes de Oca, Alireza S Alavi, Nick Vitali, Sabyasachi Bhattacharya, Christina Blackwell, et al.. Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo. Molecular Cancer Therapeutics, 2021, 20 (10), pp.1941 - 1955. ⟨10.1158/1535-7163.mct-21-0035⟩. ⟨hal-03568613⟩
66 Consultations
213 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More